Federal officials have awarded $9 million to a North Carolina drugmaker to help bring an anti-Alzheimer’s drug thru a clinical trial.
Research Triangle Park, N.C.-based pharma firm T3D Therapeutics says the money will be doled out over the next four years to support the T3D PIONEER study, a Phase II trial designed to test the safety and efficacy of its candidate pill T3D-959.
PIONEER hopes to recruit 252 adults with mild-to-moderate Alzheimer’s disease and give them either one of three doses of T3D-959 or a placebo for 24 weeks. The trial is supposed to start next year.
The money comes from a grant through the National Institute on Aging, a division of the National Institutes of Health.